Yamazaki, H.; Suzuki, G.; Aibe, N.; Shimizu, D.; Kimoto, T.; Masui, K.; Yoshida, K.; Nakamura, S.; Hashimoto, Y.; Okabe, H.
Ultrahypofractionated Radiotherapy versus Conventional to Moderate Hypofractionated Radiotherapy for Clinically Localized Prostate Cancer. Cancers 2022, 14, 195.
https://doi.org/10.3390/cancers14010195
AMA Style
Yamazaki H, Suzuki G, Aibe N, Shimizu D, Kimoto T, Masui K, Yoshida K, Nakamura S, Hashimoto Y, Okabe H.
Ultrahypofractionated Radiotherapy versus Conventional to Moderate Hypofractionated Radiotherapy for Clinically Localized Prostate Cancer. Cancers. 2022; 14(1):195.
https://doi.org/10.3390/cancers14010195
Chicago/Turabian Style
Yamazaki, Hideya, Gen Suzuki, Norihiro Aibe, Daisuke Shimizu, Takuya Kimoto, Koji Masui, Ken Yoshida, Satoaki Nakamura, Yasutoshi Hashimoto, and Haruumi Okabe.
2022. "Ultrahypofractionated Radiotherapy versus Conventional to Moderate Hypofractionated Radiotherapy for Clinically Localized Prostate Cancer" Cancers 14, no. 1: 195.
https://doi.org/10.3390/cancers14010195
APA Style
Yamazaki, H., Suzuki, G., Aibe, N., Shimizu, D., Kimoto, T., Masui, K., Yoshida, K., Nakamura, S., Hashimoto, Y., & Okabe, H.
(2022). Ultrahypofractionated Radiotherapy versus Conventional to Moderate Hypofractionated Radiotherapy for Clinically Localized Prostate Cancer. Cancers, 14(1), 195.
https://doi.org/10.3390/cancers14010195